Comparison of the response to treatment between Asian and Caucasian men with benign prostatic hyperplasia: Long-term results from the combination of dutasteride and tamsulosin study

Byung Ha Chung, Seung Hwan Lee, Claus Roehrborn, Paul F. Siami, Kim Major-Walker, Timothy H. Wilson, Francesco Montorsi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The Combination of Avodart and Tamsulosin study was a 4-year, randomized, double-blind study of the efficacy and safety of dutasteride and tamsulosin, alone or in combination, in men with moderate-to-severe benign prostatic hyperplasia. In this post-hoc investigation, we analyzed primary and secondary end-points from the Combination of Avodart and Tamsulosin study in Asian (n=325) and Caucasian men (n=4259). The incidence of acute urinary retention or benign prostatic hyperplasia-related surgery did not differ significantly between treatment groups in the Asian subpopulation. In Caucasian men, the incidence of acute urinary retention/benign prostatic hyperplasia-related surgery was significantly lower in the combination therapy group compared with the tamsulosin monotherapy group (P<0.001), but not compared with dutasteride monotherapy. Combination therapy significantly increased the time to benign prostatic hyperplasia clinical progression and resulted in improved International Prostate Symptom Score, maximum urinary flow rate, quality of life, and reduced prostate volume in Asian and Caucasian men who received combination therapy compared with tamsulosin monotherapy. Combination therapy also significantly improved (P<0.05) time to benign prostatic hyperplasia clinical progression, International Prostate Symptom Score, maximum urinary flow rate and quality of life versus dutasteride in the Caucasian subpopulation. The adverse-event profile was comparable between subpopulations. In conclusion, Asian and Caucasian men respond similarly to these treatments, despite apparent racial differences in 5α-reductase activity.

Original languageEnglish (US)
Pages (from-to)1031-1035
Number of pages5
JournalInternational Journal of Urology
Volume19
Issue number11
DOIs
StatePublished - Nov 2012

Fingerprint

tamsulosin
Prostatic Hyperplasia
Prostate
Urinary Retention
Quality of Life
Therapeutics
Incidence
Group Psychotherapy
Double-Blind Method
Oxidoreductases
Dutasteride
Safety

Keywords

  • Asian
  • Benign prostatic hyperplasia
  • Caucasian
  • Dutasteride
  • Tamsulosin

ASJC Scopus subject areas

  • Urology

Cite this

Comparison of the response to treatment between Asian and Caucasian men with benign prostatic hyperplasia : Long-term results from the combination of dutasteride and tamsulosin study. / Chung, Byung Ha; Lee, Seung Hwan; Roehrborn, Claus; Siami, Paul F.; Major-Walker, Kim; Wilson, Timothy H.; Montorsi, Francesco.

In: International Journal of Urology, Vol. 19, No. 11, 11.2012, p. 1031-1035.

Research output: Contribution to journalArticle

Chung, Byung Ha ; Lee, Seung Hwan ; Roehrborn, Claus ; Siami, Paul F. ; Major-Walker, Kim ; Wilson, Timothy H. ; Montorsi, Francesco. / Comparison of the response to treatment between Asian and Caucasian men with benign prostatic hyperplasia : Long-term results from the combination of dutasteride and tamsulosin study. In: International Journal of Urology. 2012 ; Vol. 19, No. 11. pp. 1031-1035.
@article{021578e107f946899e08539e78828b44,
title = "Comparison of the response to treatment between Asian and Caucasian men with benign prostatic hyperplasia: Long-term results from the combination of dutasteride and tamsulosin study",
abstract = "The Combination of Avodart and Tamsulosin study was a 4-year, randomized, double-blind study of the efficacy and safety of dutasteride and tamsulosin, alone or in combination, in men with moderate-to-severe benign prostatic hyperplasia. In this post-hoc investigation, we analyzed primary and secondary end-points from the Combination of Avodart and Tamsulosin study in Asian (n=325) and Caucasian men (n=4259). The incidence of acute urinary retention or benign prostatic hyperplasia-related surgery did not differ significantly between treatment groups in the Asian subpopulation. In Caucasian men, the incidence of acute urinary retention/benign prostatic hyperplasia-related surgery was significantly lower in the combination therapy group compared with the tamsulosin monotherapy group (P<0.001), but not compared with dutasteride monotherapy. Combination therapy significantly increased the time to benign prostatic hyperplasia clinical progression and resulted in improved International Prostate Symptom Score, maximum urinary flow rate, quality of life, and reduced prostate volume in Asian and Caucasian men who received combination therapy compared with tamsulosin monotherapy. Combination therapy also significantly improved (P<0.05) time to benign prostatic hyperplasia clinical progression, International Prostate Symptom Score, maximum urinary flow rate and quality of life versus dutasteride in the Caucasian subpopulation. The adverse-event profile was comparable between subpopulations. In conclusion, Asian and Caucasian men respond similarly to these treatments, despite apparent racial differences in 5α-reductase activity.",
keywords = "Asian, Benign prostatic hyperplasia, Caucasian, Dutasteride, Tamsulosin",
author = "Chung, {Byung Ha} and Lee, {Seung Hwan} and Claus Roehrborn and Siami, {Paul F.} and Kim Major-Walker and Wilson, {Timothy H.} and Francesco Montorsi",
year = "2012",
month = "11",
doi = "10.1111/j.1442-2042.2012.03091.x",
language = "English (US)",
volume = "19",
pages = "1031--1035",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Comparison of the response to treatment between Asian and Caucasian men with benign prostatic hyperplasia

T2 - Long-term results from the combination of dutasteride and tamsulosin study

AU - Chung, Byung Ha

AU - Lee, Seung Hwan

AU - Roehrborn, Claus

AU - Siami, Paul F.

AU - Major-Walker, Kim

AU - Wilson, Timothy H.

AU - Montorsi, Francesco

PY - 2012/11

Y1 - 2012/11

N2 - The Combination of Avodart and Tamsulosin study was a 4-year, randomized, double-blind study of the efficacy and safety of dutasteride and tamsulosin, alone or in combination, in men with moderate-to-severe benign prostatic hyperplasia. In this post-hoc investigation, we analyzed primary and secondary end-points from the Combination of Avodart and Tamsulosin study in Asian (n=325) and Caucasian men (n=4259). The incidence of acute urinary retention or benign prostatic hyperplasia-related surgery did not differ significantly between treatment groups in the Asian subpopulation. In Caucasian men, the incidence of acute urinary retention/benign prostatic hyperplasia-related surgery was significantly lower in the combination therapy group compared with the tamsulosin monotherapy group (P<0.001), but not compared with dutasteride monotherapy. Combination therapy significantly increased the time to benign prostatic hyperplasia clinical progression and resulted in improved International Prostate Symptom Score, maximum urinary flow rate, quality of life, and reduced prostate volume in Asian and Caucasian men who received combination therapy compared with tamsulosin monotherapy. Combination therapy also significantly improved (P<0.05) time to benign prostatic hyperplasia clinical progression, International Prostate Symptom Score, maximum urinary flow rate and quality of life versus dutasteride in the Caucasian subpopulation. The adverse-event profile was comparable between subpopulations. In conclusion, Asian and Caucasian men respond similarly to these treatments, despite apparent racial differences in 5α-reductase activity.

AB - The Combination of Avodart and Tamsulosin study was a 4-year, randomized, double-blind study of the efficacy and safety of dutasteride and tamsulosin, alone or in combination, in men with moderate-to-severe benign prostatic hyperplasia. In this post-hoc investigation, we analyzed primary and secondary end-points from the Combination of Avodart and Tamsulosin study in Asian (n=325) and Caucasian men (n=4259). The incidence of acute urinary retention or benign prostatic hyperplasia-related surgery did not differ significantly between treatment groups in the Asian subpopulation. In Caucasian men, the incidence of acute urinary retention/benign prostatic hyperplasia-related surgery was significantly lower in the combination therapy group compared with the tamsulosin monotherapy group (P<0.001), but not compared with dutasteride monotherapy. Combination therapy significantly increased the time to benign prostatic hyperplasia clinical progression and resulted in improved International Prostate Symptom Score, maximum urinary flow rate, quality of life, and reduced prostate volume in Asian and Caucasian men who received combination therapy compared with tamsulosin monotherapy. Combination therapy also significantly improved (P<0.05) time to benign prostatic hyperplasia clinical progression, International Prostate Symptom Score, maximum urinary flow rate and quality of life versus dutasteride in the Caucasian subpopulation. The adverse-event profile was comparable between subpopulations. In conclusion, Asian and Caucasian men respond similarly to these treatments, despite apparent racial differences in 5α-reductase activity.

KW - Asian

KW - Benign prostatic hyperplasia

KW - Caucasian

KW - Dutasteride

KW - Tamsulosin

UR - http://www.scopus.com/inward/record.url?scp=84868192391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868192391&partnerID=8YFLogxK

U2 - 10.1111/j.1442-2042.2012.03091.x

DO - 10.1111/j.1442-2042.2012.03091.x

M3 - Article

C2 - 22774774

AN - SCOPUS:84868192391

VL - 19

SP - 1031

EP - 1035

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

IS - 11

ER -